Epacadostat is under clinical development by Incyte and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II drugs for Dedifferentiated Liposarcoma does not have ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Earlier this week, the American Cancer Society released the full list of 245 new and renewed research grants that were ...

written by Jeronimo Garcialopez De Llano, Maria Fernanda Mijares, Vanitha Vasudevan, Rodrigo Arrangoiz, Amit Sastry, Frank De la Cruz, Jennifer Fernandez Garcia, Adrian Legaspi, ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

Liposarcoma (LPS) is the most common soft tissue sarcoma (STS ... published in 2020 (2), the LPS subtypes comprise atypical lipomatous tumor (ATL)/well-differentiated LPS (WDLPS), dedifferentiated LPS ...

The in vivo localization studies presented here show that CKGGRAKDC targets the white adipose vasculature without a detectable preference for any particular anatomical white fat depot. The uptake ...

Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...

1 Service de Chirurgie Orthopédique et Traumatologique, Cliniques Universitaires Saint-Luc, Bruxelles, Belgique 2 Service de Chirurgie Vasculaire et Thoracique, Cliniques Universitaires Saint-Luc, ...